ADAM17 and breast carcinoma: Based on these findings, it will be of great interest to examine whether the reported effect of PKCα on tumour cell behaviour involves its stimulatory effect on ADAM17, HB-EGF-shedding, and subsequent EGFR activation, which are all know drivers in breast cancer progression.